AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6366769
Drug: Penicillin therapy
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin therapy
Trial: 8078529
Drug: Budesonide 9
RxNorm normalized name: budesonide 9 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 9 mg daily
Trial: 8078529
Drug: Budesonide 15
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide 15 mg daily
Trial: 2462341
Drug: Antiarrhythmic drugs
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drugs (encainide, flecainide, moricizine, imipramine)
Trial: 55647
Drug: B.C.G. treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B.C.G. treatment
Trial: 55647
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no B.C.G.)
Trial: 31707805
Drug: Rivaroxaban 15
RxNorm normalized name: rivaroxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 15 mg od plus single antiplatelet therapy (SAPT)
Trial: 31707805
Drug: Rivaroxaban 2.5
RxNorm normalized name: rivaroxaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5 mg bid plus dual antiplatelet therapy (DAPT)
Trial: 31707805
Drug: Warfarin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin plus DAPT
Trial: 28109423
Drug: Policy proposals
RxNorm normalized name: Polivy
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Policy proposals to restrict SNAP benefits based on nutrition quality (e.g., excluding sugary drinks)
Trial: 23990895
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) consisting of 12 weekly sessions of either cognitive therapy (n=41) or prolonged exposure (PE, n=49), starting 29.8±5.7 days after ED admission
Trial: 21831508
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg p.o. three times daily)
Trial: 21831508
Drug: N-acetyl-cysteine (NAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl-cysteine (NAC) (600 mg p.o. three times daily)
Trial: 11788129
Drug: Micronized fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized fenofibrate treatment
Trial: 9750032
Drug: 2 years
RxNorm normalized name: Childrens Panadol 5 - 12 Years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 years of daily uracil/tegafur (UFT)
Trial: 3284310
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (MEX-Q)
Trial: 3284310
Drug: Drug free
RxNorm normalized name: Tenscare Pain Aide Drug Free Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug free
Trial: 26959668
Drug: Telephone-based problem-solving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based problem-solving treatment (PST)
Trial: 24176498
Drug: Tritanrix HB+Hib
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tritanrix HB+Hib (first dose) and Quinvaxem (second/third doses)
Trial: 24176498
Drug: Quinvaxem (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinvaxem (three doses)
Trial: 20529401
Drug: MM supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MM supplement with improved gruel (MMGG)
Trial: 3033751
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment radiotherapy and polychemotherapy (C.A.P. + V.D.S.)
Trial: 3033751
Drug: Split‐dose irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split‐dose irradiation alone
Trial: 29415891
Drug: gmDC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gmDC treatment (23 patients)
Trial: 29415891
Drug: gmDC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gmDC vaccine (12 acute myeloid leukemia patients)
Trial: 29415891
Drug: Standard donor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard donor lymphocyte infusion (25 patients)
Trial: 29415891
Drug: gmDC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gmDC treatment (35 patients total)
Trial: 23589106
Drug: Vaccination in
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination in combination with MDSC targeted therapy with all‐trans‐retinoic acid (ATRA) (Arm C)
Trial: 20608293
Drug: Rotation-oscillation 'On'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotation-oscillation 'On' (Oral-B Triumph with FlossAction brush head)
Trial: 18855824
Drug: Cocaine self-administration
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine self-administration sessions (randomized, placebo-controlled)
Trial: 14675918
Drug: High-risk features
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-risk features (T-PSA >10 ng/ml or Gleason sum >=7)
Trial: 10973768
Drug: Trimetazidine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (40 mg intravenous bolus followed by 60 mg continuous infusion for 48 hours)
Trial: 8827741
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam 0.75 mg.kg‐1
Trial: 25313065
Drug: Sulforaphane (50-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulforaphane (50-150 µmol daily for 18 weeks)
Trial: 18721251
Drug: Pilocarpine/timolol maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine/timolol maleate fixed combination (PTFC) given twice daily
Trial: 17133211
Drug: MK-0518 100
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0518 100 mg
Trial: 17133211
Drug: MK-0518 200
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0518 200 mg
Trial: 17133211
Drug: MK-0518 400
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0518 400 mg
Trial: 17133211
Drug: MK-0518 600
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0518 600 mg
Trial: 10698133
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate (75 mg/kg, maximum 2 g)
Trial: 10698133
Drug: Midazolam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.5 mg/kg, maximum 10 mg)
Trial: 24091718
Drug: Depression treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depression treatment
Trial: 22241604
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of laboratory‐expanded, skin‐derived fibroblasts suspended in autologous plasma
Trial: 22241604
Drug: Ultrasound-guided injection
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided injection of local anesthetic and physiotherapy
Trial: 20531220
Drug: Lamotrigine (dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (dosing ranged from 12.5 to 300 mg/d)
Trial: 8824694
Drug: Acute propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute propranolol (0.15 mg kg‐1 i.v.)
Trial: 8824694
Drug: Chronic propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic propranolol (80 mg three times daily for 2 weeks)
Trial: 28031053
Drug: Golimumab 50
RxNorm normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golimumab 50 mg or 100 mg injections every 4 weeks through week 24
Trial: 28031053
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections every 4 weeks through week 24
Trial: 25910610
Drug: High uterosacral
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High uterosacral vault suspension (HUVS)
Trial: 19117152
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg bupivacaine
Trial: 9201844
Drug: Premarin, 1
RxNorm normalized name: Premarin, 1.25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premarin, 1 mg/kg intravenously in the immediate postoperative period
Trial: 1492408
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of evening primrose oil and fish oil (GLA, EPA, DHA)
Trial: 30701988
Drug: Sunitinib (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (37.5 mg on a continuous daily‐dosing regimen)
Trial: 26956689
Drug: Adjuvant XELOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant XELOX (capecitabine plus oxaliplatin); capecitabine 1000 mg/m2 twice daily on days 1-14, oxaliplatin 130 mg/m2 on day 1 for eight 3-week cycles
Trial: 20980493
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg folic acid/d
Trial: 20980493
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg folic acid/d
Trial: 20980493
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg folic acid/d
Trial: 11359167
Drug: Vitamins C
RxNorm normalized name: MULTIVITAMINS CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamins C and E (1 g ascorbic acid and 600 IU d-alpha-tocopherol daily before diving)
Trial: 9236432
Drug: Perindopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4 mg/d PO for up to 36 days)
Trial: 8179973
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg four times a day)
Trial: 21429809
Drug: Subcutaneous methylnaltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous methylnaltrexone 12 mg once daily (QD)
Trial: 21429809
Drug: Subcutaneous methylnaltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous methylnaltrexone 12 mg every other day (alternate-day dosing)
Trial: 12687868
Drug: Cardioverter defibrillator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardioverter defibrillator shock therapy
Trial: 8823558
Drug: Itraconazole 100
RxNorm normalized name: itraconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 100 mg once daily for six weeks
Trial: 8823558
Drug: Itraconazole 50
RxNorm normalized name: ITRACONAZOLE 50MG/5ML SOLN,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 50 mg once daily for six weeks
Trial: 1315661
Drug: Deferral of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferral of treatment
Trial: 29924010
Drug: LED therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LED therapy (n = 30)
Trial: 29924010
Drug: Bath therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bath therapy (n = 30)
Trial: 27129125
Drug: Tofacitinib 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 30 mg twice daily
Trial: 27138968
Drug: Microgynon 30®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microgynon 30® tablet (30 μg EE and 150 μg LN)
Trial: 24502751
Drug: Ecological momentary
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ecological momentary assessment using the Daytime Insomnia Symptom Scale (DISS) administered 4 times daily for 7 days.
Trial: 15018324
Drug: Single intracisternal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intracisternal injection of recombinant tPA (400 microg/ml, 500 microg/ml, 700 microg/ml, 800 microg/ml in 20 ml distilled water at pH 7)
Trial: 15018324
Drug: Single intracisternal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intracisternal injection of recombinant tPA
Trial: 10771973
Drug: Inhaled dexamethasone
RxNorm normalized name: dexamethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled dexamethasone
Trial: 30017261
Drug: Electroconvulsive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive therapy (ECT) responders and remitters
Trial: 26931279
Drug: Teriparatide (TPTD)
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teriparatide (TPTD) 20 μg/d (subcutaneous injection)
Trial: 26931279
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic Acid (ZOL) 5 mg/yr (intravenous infusion)
Trial: 24852357
Drug: Previously received
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previously received mental health treatment
Trial: 20391044
Drug: Cyanocobalamin nasal
RxNorm normalized name: cyanocobalamin nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyanocobalamin nasal spray for 8 weeks
Trial: 12094192
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy with ST-segment resolution at 90 minutes
Trial: 12094192
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy with ST-segment resolution at 180 minutes
Trial: 8948272
Drug: Alendronate 20/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 20/5 mg
Trial: 7484285
Drug: Alendronate 5
RxNorm normalized name: ALENDRONATE 5MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 5 mg
Trial: 1682685
Drug: Capsaicin (NANC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicin (NANC stimulant)
Trial: 29921404
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of contraceptive pill + local treatment + pulsed‐vacuum light (Group I)
Trial: 29921404
Drug: Local treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local treatment only (Group III)
Trial: 29921404
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of contraceptives + pulsed‐vacuum light (Group II)
Trial: 25057173
Drug: Vandetanib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib (100 mg/day) plus docetaxel (75 mg/m(2) every 21 days)
Trial: 22173910
Drug: Cocoa-liquor-free control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa-liquor-free control chocolate (CC)
Trial: 17205032
Drug: Erythromycin 200
RxNorm normalized name: ERYTHROMYCIN 200 mg in 2 g TOPICAL POWDER [API E.M. Erythromycin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 200 mg intravenously twice a day
Trial: 17205032
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg intravenously four times daily
Trial: 17205032
Drug: Rescue combination
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue combination therapy (open-label)
Trial: 12509907
Drug: Tinnitus retraining
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinnitus retraining therapy (TRT) with drugs
Trial: 12509907
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with tinnitus masking and drugs
Trial: 7644082
Drug: Oral sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sumatriptan 25 mg, 50 mg, or 100 mg
Trial: 952109
Drug: Combined polychemotherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined polychemotherapy with high doses of cytostatics applied intermittently after radical surgery.
Trial: 28866675
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (2 intravitreal loading doses at 4-week intervals)
Trial: 23744759
Drug: HPβCD-diclofenac (IV)
RxNorm normalized name: HP-beta-CD
DrugBank: Hydroxypropyl betadex (DB15379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPβCD-diclofenac (IV) 18.75 mg
Trial: 23744759
Drug: HPβCD-diclofenac (IV)
RxNorm normalized name: HP-beta-CD
DrugBank: Hydroxypropyl betadex (DB15379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPβCD-diclofenac (IV) 37.5 mg
Trial: 23744759
Drug: Cataflam 50
RxNorm normalized name: Cataflam 50mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cataflam 50 mg (oral)
Trial: 17147046
Drug: Sodium enoxaparin
RxNorm normalized name: Enoxaparin Sodium
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium enoxaparin administered subcutaneously at a dose of 4,000 IU once a day for 10 days, combined with venovenous hemofiltration performed at the first and last day of the protocol
Trial: 17147046
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (cortisone, vasoactive agents, and vitamin complexes) administered in physiological solution intravenously twice daily for 10 days
Trial: 10840422
Drug: Monthly BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly BCG
Trial: 10840422
Drug: Alternating monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Alternating monthly interferon-alpha and BCG
Trial: 2085986
Drug: Norfloxacin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (800 mg)
Trial: 3107462
Drug: Thiamphenicol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamphenicol (2.5 g)
Trial: 20002719
Drug: Paracetamol 15
RxNorm normalized name: Paracetamol 150 mg and sodium salicylate 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 15 mg/kg/dose every 4 h
Trial: 20002719
Drug: Ibuprofen 10
RxNorm normalized name: ibuprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 10 mg/kg/dose every 8 h
Trial: 20002719
Drug: Paracetamol and
RxNorm normalized name: Paracetamol and tramadol only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol and Ibuprofen (both groups)
Trial: 12765607
Drug: Antibodies against
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies against beta-amyloid (aggregated Abeta(42))
Trial: 6145426
Drug: fluperlapine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluperlapine 5 mg
Trial: 6145426
Drug: fluperlapine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluperlapine 10 mg
Trial: 6145426
Drug: clozapine 5
RxNorm normalized name: clozapine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clozapine 5 mg
Trial: 6145426
Drug: clozapine 10
RxNorm normalized name: clozapine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clozapine 10 mg
Trial: 3527402
Drug: Chlorambucil (CB)
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorambucil (CB) and Prednisone (P) for induction therapy
Trial: 25795406
Drug: Trabectedin (1·2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin (1·2 mg/m² via central venous line over 24 h on day 1 of a 21 day treatment cycle)
Trial: 23940307
Drug: Spironolactone (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (titrated to 25 or 50 mg daily)
Trial: 20886786
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (Duphalac)
Trial: 14555263
Drug: Intravenous ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ibandronate (2 mg every 3 months) and calcium (1000 mg daily)
Trial: 14555263
Drug: Intravenous ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ibandronate (2 mg every 3 months) and calcium (1000 mg daily) with 700 IU vitamin D daily in the second year
Trial: 11078987
Drug: Urinary iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Urinary iodine concentration (UIC) measured in microg/l
Trial: 1316330
Drug: Fluoxetine 60
RxNorm normalized name: fluoxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 60 mg daily for 14 days
Trial: 2579953
Drug: Dextran 40
RxNorm normalized name: Dextran 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextran 40 peroperatively plus 0.5 g aspirin a day for 10 days